Patient Name : Mrs.

RUBI SHARMA Collected : 09/Dec/2024 02:48PM

Age/Gender : 30 Y 0 M 0 D /F Received : 09/Dec/2024 05:26PM
UHID/MR No : DLAA.0000003136 Reported : 09/Dec/2024 05:49PM
Visit ID : DLAAOPV3734 Status : Final Report
Ref Doctor : DR.LATA RAJPUT Client Name : DDC DR LATA S NIRMITI HOSPITAL
IP/OP NO : Center location : BHOSARI,Pune

DEPARTMENT OF COAGULATION

Test Name Result Unit Bio. Ref. Interval Method

PROTHROMBIN TIME (PT/INR) , SODIUM CITRATE PLASMA
Prothrombin Time 15.6 Seconds 13.2 - 17.9 Optomechanical clot
detection
Control (MNPT) 14.80 Seconds Optomechanical clot
detection
Ratio 1.05 Calculated
Prothrombin Index 94.87 % Calculated
International Normalized Ratio (INR) 1.06 Calculated

Comment:
INTERNATIONAL NORMALIZED RATIO
REFERENCE GROUP
(INR)
NORMAL POPULATION 0.9 – 1.1
PATIENTS ON ANTICOAGULANT
THERAPY
· STANDARD DOSE THERAPY 2.0 – 3.0
· HIGH DOSE THERAPY 2.5 – 3.5

INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy.Marked elevation of INR in patients receiving
oral anticoagulant therapyis a marker of excessive anticoagulation and requires prompt action; an INR below 2.0 reflects
insufficient anticoagulation.

Page 1 of 4

SIN No:CO00683906
Patient Name : Mrs.RUBI SHARMA Collected : 09/Dec/2024 02:48PM
Age/Gender : 30 Y 0 M 0 D /F Received : 09/Dec/2024 05:26PM
UHID/MR No : DLAA.0000003136 Reported : 09/Dec/2024 05:50PM
Visit ID : DLAAOPV3734 Status : Final Report
Ref Doctor : DR.LATA RAJPUT Client Name : DDC DR LATA S NIRMITI HOSPITAL
IP/OP NO : Center location : BHOSARI,Pune

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

GLUCOSE, RANDOM , SODIUM 94 mg/dL 70 - 140 Glucose oxidase
FLUORIDE PLASMA (R)

Page 2 of 4

SIN No:BI23126331
Patient Name : Mrs.RUBI SHARMA Collected : 09/Dec/2024 02:48PM
Age/Gender : 30 Y 0 M 0 D /F Received : 09/Dec/2024 05:25PM
UHID/MR No : DLAA.0000003136 Reported : 09/Dec/2024 06:05PM
Visit ID : DLAAOPV3734 Status : Final Report
Ref Doctor : DR.LATA RAJPUT Client Name : DDC DR LATA S NIRMITI HOSPITAL
IP/OP NO : Center location : BHOSARI,Pune

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

LIVER FUNCTION TEST (LFT) , SERUM
BILIRUBIN, TOTAL 0.50 mg/dL 0.20-1.30 DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT) 0.30 mg/dL 0.0-0.3 Calculated
BILIRUBIN (INDIRECT) 0.20 mg/dL 0.0-1.1 Dual Wavelength
ALANINE AMINOTRANSFERASE 188 U/L 9-52 UV with P-5-P
(ALT/SGPT)
ASPARTATE AMINOTRANSFERASE 88.0 U/L 14-36 UV with P-5-P
(AST/SGOT)
AST (SGOT) / ALT (SGPT) RATIO (DE 0.5 <1.15 Calculated
RITIS)
ALKALINE PHOSPHATASE 160.00 U/L 38-126 p-nitrophenyl
phosphate
PROTEIN, TOTAL 6.50 g/dL 6.3-8.2 Biuret
ALBUMIN 3.20 g/dL 3.5 - 5 Bromocresol Green
GLOBULIN 3.30 g/dL 2.0-3.5 Calculated
A/G RATIO 0.97 0.9-2.0 Calculated

Comment:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of
bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:
1. Hepatocellular Injury:
*AST – Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT –
Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also
correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) – In case of
hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in
NAFLD, Wilsons’s diseases, Cirrhosis, but the increase is usually not >2.
2. Cholestatic Pattern:*ALP – Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in
pregnancy, impacted by age and sex.*Bilirubin elevated- predominantly direct , To establish the hepatic origin correlation with
elevated GGT helps.
3. Synthetic function impairment:*Albumin- Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
4. Associated tests for assessment of liver fibrosis - Fibrosis-4 and APRI Index.

*** End Of Report ***

Page 3 of 4

SIN No:BI23126330
Patient Name : Mrs.RUBI SHARMA Collected : 09/Dec/2024 02:48PM
Age/Gender : 30 Y 0 M 0 D /F Received : 09/Dec/2024 05:25PM
UHID/MR No : DLAA.0000003136 Reported : 09/Dec/2024 06:05PM
Visit ID : DLAAOPV3734 Status : Final Report
Ref Doctor : DR.LATA RAJPUT Client Name : DDC DR LATA S NIRMITI HOSPITAL
IP/OP NO : Center location : BHOSARI,Pune

DEPARTMENT OF BIOCHEMISTRY

Page 4 of 4

SIN No:BI23126330
 Patient Name : Mrs.RUBI SHARMA Collected : 09/Dec/2024 02:48PM
Age/Gender : 30 Y 0 M 0 D /F Received : 09/Dec/2024 05:25PM
UHID/MR No : DLAA.0000003136 Reported : 09/Dec/2024 06:05PM
Visit ID : DLAAOPV3734 Status : Final Report
Ref Doctor : DR.LATA RAJPUT Client Name : DDC DR LATA S NIRMITI HOSPITAL
IP/OP NO : Center location : BHOSARI,Pune

TERMS AND CONDITIONS GOVERNING THIS REPORT

1. Reported results are for information and interpretation of the referring doctor or such other medical professionals,
who understandreporting units, reference ranges and limitation of technologies.Laboratories not be responsible for any
interpretation whatsoever.
2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the
verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient (within subject biological variation).
4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be
communicated to the assigned regulatory bodies.
5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
the laboratory.
6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.

SIN No:BI23126330